Pharsight

Noden Pharma patents expiration

1. Goprelto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10894012 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10857095 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10231961 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10413505 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US9867815 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US11040032 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10016407 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10149843 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10420760 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10933060 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10973811 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

US10987347 NODEN PHARMA Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022

Drugs and Companies using COCAINE HYDROCHLORIDE ingredient

NCE-1 date: 14 December, 2021

Market Authorisation Date: 14 December, 2017

Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic to the mucous membranes; Method of administering a local anesthetic to the mucous membr...

Dosage: SOLUTION;NASAL

More Information on Dosage

GOPRELTO family patents

Family Patents

2. Tekturna patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5559111 NODEN PHARMA δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jul, 2018

(5 years ago)

US5559111

(Pediatric)

NODEN PHARMA δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jan, 2019

(5 years ago)

US8617595 NODEN PHARMA Galenic formulations of organic compounds
Feb, 2026

(1 year, 8 months from now)

US8617595

(Pediatric)

NODEN PHARMA Galenic formulations of organic compounds
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 05, 2012

Drugs and Companies using ALISKIREN HEMIFUMARATE ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 05 March, 2007

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of TEKTURNA before it's drug patent expiration?
More Information on Dosage

TEKTURNA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Tekturna Hct patents expiration

TEKTURNA HCT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5559111 NODEN PHARMA δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jul, 2018

(5 years ago)

US5559111

(Pediatric)

NODEN PHARMA δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides
Jan, 2019

(5 years ago)

US9023893 NODEN PHARMA Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
Mar, 2022

(2 years ago)

US8618172 NODEN PHARMA Galenical formulations of organic compounds
Jul, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 05, 2012
New Indication(I-600) Jul 16, 2012

Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient

NCE-1 date: 06 March, 2011

Market Authorisation Date: 18 January, 2008

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of TEKTURNA HCT before it's drug patent expiration?
More Information on Dosage

TEKTURNA HCT family patents

Family Patents